The Development and Evaluation of Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR)
用于药物使用障碍远程管理的增强型数字化学感应嗅觉训练的开发和评估(编辑)
基本信息
- 批准号:10741580
- 负责人:
- 金额:$ 5.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-01 至 2023-04-30
- 项目状态:已结题
- 来源:
- 关键词:Accident and Emergency departmentAdoptionAfrican American populationAgonistAlcohol withdrawal syndromeBeta-caryophylleneCOVID-19 pandemicCellular PhoneCocaineCocaine use disorderCommunitiesDataDevelopmentDisadvantaged minorityDisparity populationEvaluationFeedbackFundingHealth Insurance Portability and Accountability ActHispanic AmericansIndustryInnovation CorpsIntelligenceInternetInterventionIntoxicationLanguageLeadershipMeasuresMentorshipMethamphetamineMethamphetamine use disorderPatientsPharmaceutical PreparationsPhasePhysiologicalPopulationProviderPsychophysicsPulse RatesRemote managementResearchRunningSecureSensorySmall Business Innovation Research GrantStimulantSubstance Use DisorderSurveysTestingTherapeuticTrainingUniversitiesVoiceWashingtonWithdrawalalcohol use disordercocaine usecombinatorialcravingdigitaldigital treatmenteffectiveness/implementation studyefficacy studyilliteracyinnovationmHealthmarginalizationmen who have sex with menmobile computingneighborhood disadvantageopioid use disorderopioid withdrawalpatient orientedproduct developmentprogramspsychologicrandomized trialsensorsexual minority groupsocial disparitiesstimulant usestimulant use disordersubstance usesubstance use treatmenttreatment as usualwardweb portalwireless fidelity
项目摘要
ABSTRACT
The Development and Evaluation of Enhanced Digital-Chemosensory-Based Olfactory Training for
Remote Management of Substance Use Disorders (EDITOR) is a project to develop a sustainable, scalable,
and patient-centered mobile health platform, comprised of (1) patient-facing culturally-adapted digital-
chemosensory therapeutic for stimulant, alcohol and opioid use disorders, sensors for acquisition of objective
physiological measures of substance intoxication and withdrawal, and application for running and interpreting
the interventions and sensory acquisition programs; and (2) a provider-facing web portal, for substance use
disorder treatment in socially-disadvantaged and sexual minority populations. Management of substance use
disorders (SUD) mostly involve direct contact between patients and providers, but the precedence of COVID-
19 pandemic has elevated the need for patient-centered remote management of SUD. While digital
therapeutics and mobile health platforms provide avenues for remote management, our communities of African
Americans (AA), Hispanic-Americans (HA) and other socially disadvantaged populations lag in adoption of
these mobile platforms, due to inability to read, digital illiteracy, lack of access to smartphones, absence of
reliable Wi-Fi or internet, and financial constraints. Moreover, while interventions exist for Opioid Use Disorders
(OUD), there are no drugs for cocaine or stimulant use disorders. Underserved AA and HA communities with
OUD, particularly marginalized men who have sex with men (MSM), have more severe co-existing cocaine,
methamphetamine, and alcohol use disorders; and digital solutions for these populations are lacking. Providers
on the other hand, lack well-adapted, intelligent-based physiological and psychophysical acquisition platforms
to guide remote agonist management of opioid and alcohol withdrawal. Through Phase I SBIR, EVON Medics
developed a combinatorial digital chemosensory-based orbitofrontal cortex training for Opioid Use Disorder
(CBOT). Based on the limitations of CBOT for our socially disadvantaged AA, HA and MSM population, we
recently revised the platform for treatment of stimulant and alcohol use disorder, by including beta-
caryophyllene chemosensory stimulation. We propose further product development, with innovative changes to
the patient-facing platform and a new provider-facing platform to guide remote management of OUD, Stimulant
(cocaine and methamphetamine) use and alcohol use disorders through Fast-Track SBIR funding. In Phase I,
we will configure the patient-facing platform with: voice commands, different languages especially for the non-
English speaking, non-Wi-Fi or internet-dependent connectivity solution, reliable pupillary, pulse rate and spo2
physiological acquisitions and psychological (e.g., craving) surveys; and the provider-facing component to
provide interpretation of patients’ data in a HIPAA-secure portal. We will do preliminary testing in 3 substance
use programs, Howard University emergency room, and community populations in the under-served Ward 8
communities in Washington, DC. In Phase II, we will perform a pilot randomized trial of EDITOR compared to
treatment as usual and CBOT for office-based treatment of SUDs in several federal funded programs
associated with Evon Medics and Howard University. Upon completion of Phases I and II, we will be poised to
expand the research to either a larger, Phase III efficacy study, or an implementation study of effectiveness in
the real-world setting through commercial partnerships developed over the course of this project. To the best of
our knowledge, this will be the first evaluation of Digital-Chemosensory-Based platform for remote
management of SUD, culturally adapted for socially disadvantaged communities and populations.
摘要
基于数字化感觉的嗅觉训练的开发与评价
物质使用障碍的远程管理(EDITOR)是一个项目,以开发一个可持续的,可扩展的,
和以患者为中心的移动的健康平台,包括(1)面向患者的适应文化的数字-
用于兴奋剂、酒精和阿片类药物使用障碍的化学感觉治疗剂、用于获得目标的传感器
物质中毒和戒断的生理学测量以及在跑步和解释中的应用
干预和感觉获得计划;(2)面向提供者的门户网站,用于物质使用
社会弱势群体和性少数群体的疾病治疗。物质使用管理
疾病(SUD)主要涉及患者和提供者之间的直接接触,但COVID-
19大流行提高了对以患者为中心的SUD远程管理的需求。而数字
治疗和移动的健康平台为远程管理提供了途径,我们的非洲社区
美国人(AA),西班牙裔美国人(HA)和其他社会弱势群体在采用
这些移动的平台,由于无法阅读,数字文盲,缺乏智能手机,缺乏
可靠的Wi-Fi或互联网,以及财务限制。此外,虽然存在阿片类药物使用障碍的干预措施,
(OUD)没有治疗可卡因或兴奋剂使用障碍的药物。服务不足的AA和HA社区,
OUD,特别是与男性发生性关系的边缘化男性(MSM),有更严重的共存可卡因,
甲基苯丙胺和酒精使用障碍;缺乏针对这些人群的数字解决方案。提供商
另一方面,缺乏适应性强的、基于智能的生理和心理物理获取平台
指导阿片类药物和酒精戒断的远程激动剂管理。通过第一阶段SBIR,EVON Medics
开发了一种基于组合数字化学传感器的眶额皮层训练阿片类药物使用障碍
(CBOT)。基于CBOT对我们的社会弱势AA,HA和MSM人群的限制,我们
最近修订了治疗兴奋剂和酒精使用障碍的平台,
卡环烯化学感觉刺激我们建议进一步开发产品,并进行创新性的更改,
面向患者的平台和新的面向提供者的平台,用于指导OUD、刺激剂的远程管理
(可卡因和甲基苯丙胺)使用和酒精使用障碍通过快速通道SBIR资金。在第一阶段,
我们将为面向患者的平台配置:语音命令,不同的语言,特别是针对非
英语,非Wi-Fi或互联网依赖的连接解决方案,可靠的瞳孔,脉搏率和spo 2
生理采集和心理(例如,渴望)调查;和面向提供者的组件,
在HIPAA安全门户中提供患者数据的解释。我们将在3个物质中进行初步测试
使用程序,霍华德大学急诊室,和社区人口在服务不足的病房8
在华盛顿的社区。在第二阶段,我们将进行EDITOR的试点随机试验,
在几个联邦资助的项目中,常规治疗和CBOT用于SUD的办公室治疗
与埃文医生和霍华德大学有联系。在第一和第二阶段完成后,我们将准备
将研究扩展到更大的III期疗效研究,或
通过在这个项目的过程中发展的商业伙伴关系的现实世界的设置。尽最大
据我们所知,这将是第一次评估基于数字化学传感器的远程平台,
在文化上适应社会弱势社区和人口的可持续发展管理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Charles Chiedu Nwaokobia其他文献
Charles Chiedu Nwaokobia的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Charles Chiedu Nwaokobia', 18)}}的其他基金
Development and Evaluation of Portable Compendium of Psychophysical and Physiological Tests for Alzheimer's Disease and Related Dementias (ADRD)
阿尔茨海默病和相关痴呆症(ADRD)便携式心理物理和生理测试纲要的开发和评估
- 批准号:
10699349 - 财政年份:2023
- 资助金额:
$ 5.5万 - 项目类别:
The Development and Evaluation of Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR)
用于药物使用障碍远程管理的增强型数字化学感应嗅觉训练的开发和评估(编辑)
- 批准号:
10794665 - 财政年份:2023
- 资助金额:
$ 5.5万 - 项目类别:
The Development and Evaluation of Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR)
用于药物使用障碍远程管理的增强型数字化学感应嗅觉训练的开发和评估(编辑)
- 批准号:
10469912 - 财政年份:2022
- 资助金额:
$ 5.5万 - 项目类别:
Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)
用于治疗疼痛的计算机化化学感应眼眶额网络训练 (CBOT-P) 的开发和评估
- 批准号:
10547925 - 财政年份:2022
- 资助金额:
$ 5.5万 - 项目类别:
Development and Evaluation of Computerized Olfactory Training Program (COT) for Cognitive Decline in Early Alzheimer's Disease (AD)
针对早期阿尔茨海默病 (AD) 认知衰退的计算机嗅觉训练计划 (COT) 的开发和评估
- 批准号:
10574428 - 财政年份:2018
- 资助金额:
$ 5.5万 - 项目类别:
Development and Evaluation of Computerized Olfactory Training Program (COT) for Cognitive Decline in Early Alzheimer's Disease
针对早期阿尔茨海默病认知衰退的计算机嗅觉训练计划 (COT) 的开发和评估
- 批准号:
10614897 - 财政年份:2018
- 资助金额:
$ 5.5万 - 项目类别:
Development and Evaluation of Computerized Olfactory Training Program (COT) for Cognitive Decline in Early Alzheimer's Disease (AD)
针对早期阿尔茨海默病 (AD) 认知衰退的计算机嗅觉训练计划 (COT) 的开发和评估
- 批准号:
10399659 - 财政年份:2018
- 资助金额:
$ 5.5万 - 项目类别:
Development and Evaluation of Computerized Olfactory Training Program (COT) for Cognitive Decline in Early Alzheimer's Disease (AD)
针对早期阿尔茨海默病 (AD) 认知衰退的计算机嗅觉训练计划 (COT) 的开发和评估
- 批准号:
10256329 - 财政年份:2018
- 资助金额:
$ 5.5万 - 项目类别:
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 5.5万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 5.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 5.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 5.5万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 5.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 5.5万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 5.5万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 5.5万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 5.5万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 5.5万 - 项目类别:
Standard Grant